Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) has issued an update.
On January 29, 2026, Shuttle Pharmaceuticals Holdings, Inc. amended its existing consulting agreement with Number 2 Capital Corp., a Canadian company owned by interim co-Chief Executive Officer Christopher Cooper, extending the agreement’s term to August 1, 2026, effective September 11, 2025. Under the amended arrangement, the consultant will continue to receive $20,000 per month for a 40-hour workweek, with the agreement remaining terminable by either party on 30 days’ notice or immediately for cause, and subject to standard confidentiality and non-disclosure provisions, underscoring the company’s ongoing reliance on Cooper’s leadership during this interim period.
Spark’s Take on SHPH Stock
According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.
Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.
To see Spark’s full report on SHPH stock, click here.
More about Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. is a Delaware-based company; the release does not specify its industry, primary products, services, or market focus.
Average Trading Volume: 2,755,956
Technical Sentiment Signal: Sell
Current Market Cap: $3.24M
Find detailed analytics on SHPH stock on TipRanks’ Stock Analysis page.